Table 1.
Baseline demographic and clinical characteristics of the ITT cohort
| Incident target therapy cohort | |||||
|---|---|---|---|---|---|
| All (n = 1662) | Combi mira/AM (n = 427) | OnabotulinumtoxinAa (n = 456) | SNS (n = 535) | PTNSa (n = 245) | |
| Age in years | |||||
| Mean (SD) | 62.8 (14.9) | 65.5 (15.1) | 62.3 (15) | 59.4 (13.9) | 66.6 (14.6) |
| Median (IQR) | 61 (21) | 63 (23) | 61 (22.2) | 59 (19) | 68 (21) |
| Age category, y, n (%) | |||||
| 18 to <40 | 101 (6.1%) | 18 (4.2%) | 33 (7.2%) | 40 (7.5%) | 10 (4.1%) |
| 40 to <65 | 825 (49.6%) | 196 (45.9%) | 219 (48%) | 314 (58.7%) | 96 (39.2%) |
| 65 to <75 | 321 (19.3%) | 76 (17.8%) | 92 (20.2%) | 94 (17.6%) | 60 (24.5%) |
| 75+ | 415 (25%) | 137 (32.1%) | 112 (24.6%) | 87 (16.3%) | 79 (32.2%) |
| Sex, n (%) | |||||
| Female | 1385 (83.3%) | 312 (73.1%) | 400 (87.7%) | 477 (89.2%) | 197 (80.4%) |
| Male | 277 (16.7%) | 115 (26.9%) | 56 (12.3%) | 58 (10.8%) | 48 (19.6%) |
| Elixhauser score (# of categories; unweighted) | |||||
| Mean (SD) | 1.9 (1.7) | 2.0 (1.9) | 1.9 (1.7) | 2.0 (1.6) | 1.6 (1.5) |
| Median (IQR) | 2 (2) | 2 (2) | 1.5 (2) | 2 (2) | 1 (2) |
| Selected Elixhauser index comorbidities, n (%) | |||||
| Cardiac arrhythmias | 230 (13.8%) | 62 (14.5%) | 56 (12.3%) | 77 (14.4%) | 35 (14.3%) |
| Valvular disease | 134 (8.1%) | 39 (9.1%) | 34 (7.5%) | 39 (7.3%) | 22 (9.0%) |
| Peripheral vascular disorders | 155 (9.3%) | 49 (11.5%) | 38 (8.3%) | 35 (6.5%) | 33 (13.5%) |
| Hypertension, uncomplicated | 326 (19.6%) | 90 (21.1%) | 71 (15.6%) | 145 (27.1%) | 20 (8.2%) |
| Chronic pulmonary disease | 300 (18.1%) | 75 (17.6%) | 80 (17.5%) | 107 (20.0%) | 38 (15.5%) |
| Diabetes, uncomplicated | 125 (7.5%) | 37 (8.7%) | 32 (7.0%) | 44 (8.2%) | 12 (4.9%) |
| Hypothyroidism | 362 (21.8%) | 90 (21.1%) | 109 (23.9%) | 120 (22.4%) | 43 (17.6%) |
| Obesity | 244 (14.7%) | 72 (16.9%) | 60 (13.2%) | 74 (13.8%) | 38 (15.5%) |
| Depression | 411 (24.7%) | 103 (24.1%) | 110 (24.1%) | 152 (28.4%) | 46 (18.8%) |
| OAB symptoms, n (%) | |||||
| Incontinence without urgency or frequency | 154 (9.3%) | 46 (10.8%) | 31 (6.8%) | 52 (9.7%) | 25 (10.2%) |
| Incontinence with urgency and/or frequency | 1226 (73.8%) | 264 (61.8%) | 380 (83.3%) | 393 (73.5%) | 190 (77.6%) |
| Also with codes for nocturia | 424 (25.5%) | 105 (24.6%) | 122 (26.8%) | 125 (23.4%) | 72 (29.4%) |
Note: Not all individuals in the Incident pharmacotherapy cohort will experience a target therapy.
Abbreviations: AM, antimuscarinic; IQR, interquartile range; ITT, incident target therapy; mira, mirabegron; OAB, overactive bladder; PTNS, percutaneous tibial nerve stimulation; SD, standard deviation; SNS, sacral nerve stimulation.
a
One patient receiving PTNS and onabotulinumtoxinA concurrently at index, and is included in both group.